Form 4: Altimmune Director Granted 48,800 Stock Options

Altimmune, Inc. Director Philip Hodges was granted 48,800 stock options with an exercise price of $3.92, vesting over 12 months.

Summary

• Director Philip Hodges of Altimmune, Inc. was granted 48,800 stock options.
• The options have an exercise price of $3.92 per share.
• The grant date for these options was September 25, 2025.
• The options will vest in substantially equal monthly installments over 12 months, starting from September 25, 2025.
• The expiration date for these options is September 25, 2035.
• Following this transaction, Philip Hodges beneficially owns 48,800 derivative securities directly.
• Philip Hodges also granted a Power of Attorney to Vipin K. Garg and Gregory Weaver, effective September 25, 2025, to handle his SEC filings.

Sentiment

Score: 6

Explanation: The grant of stock options to a director is generally a positive signal as it aligns management's interests with shareholders. However, it's a routine compensation event rather than a significant strategic or financial announcement, hence a moderate positive score.

Positives

• The grant of stock options to a director aligns their interests with shareholders, incentivizing long-term performance.
• The options have a 10-year expiration period, providing a long runway for potential value creation.

Negatives

• No immediate cash investment by the director, as the options were granted at a price of $0.00 (referring to the grant price of the option itself, not the exercise price).

Risks

• The vesting of options is subject to the reporting person's continued service, posing a risk of forfeiture if service terminates.
• The Power of Attorney includes an indemnification clause where the undersigned agrees to indemnify the attorney-in-fact and the Company from any demand, damage, loss, cost, or expense arising from false or misleading information provided by the undersigned.

Future Outlook

NA

Industry Context

This filing reflects a standard practice in corporate governance where equity compensation, such as stock options, is granted to directors to align their long-term interests with those of the company's shareholders. Such grants are common across the biotechnology and pharmaceutical sectors, where Altimmune operates, to attract and retain experienced leadership.

Corporate Governance

Stakeholder Impact

• Shareholders: Potential for increased alignment of director's interests with shareholder value creation due to equity compensation.
• Management: The Power of Attorney streamlines compliance for the director regarding SEC filings.

Next Steps

• Continued service by Philip Hodges to ensure full vesting of the stock options.
• Potential exercise of options by Philip Hodges in the future, subject to vesting and market conditions.

Key Dates

Recommendation

This Form 4 reports a routine grant of stock options to a director as part of their compensation. While it aligns the director's interests with shareholders, it does not provide new material information regarding the company's operational performance, financial health, or strategic direction that would warrant a change in investment recommendation. Investors should continue to hold based on broader company fundamentals and market conditions.

Keywords

Altimmune, ALT, Stock Options, Insider Transaction, Form 4, Director Compensation, Equity Grant, Philip Hodges